HIV Type 1 Genotypic Resistance in a Clinical Database Correlates with Antiretroviral Utilization
- 1 January 2004
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 20 (1) , 1-9
- https://doi.org/10.1089/088922204322749440
Abstract
We established a database of HIV-1 reverse transcriptase (RT) and protease (PR) sequences and mutations to monitor the prevalence of antiretroviral drug resistance and mutational patterns in clinical samples submitted for testing to a major U.S. reference laboratory. At the end of 1998, 80% of the clinical samples tested harbored HIV strains with genotypically predicted resistance to at least one antiretroviral (ARV) drug. By the third quarter of 2002, the frequency of genotypically predicted resistance declined to 65% of samples tested. The prevalence of both PR and nucleoside RT inhibitor resistance declined over this period, while an increase in resistance to nonnucleoside RT inhibitors was found. These genotypic results strongly correlated with a nationwide decrease in the prescription of PR and nucleoside RT inhibitors, and an increase in the prescription of nonucleoside RT inhibitors over the time period. The increased number of strains that were genotypically sensitive to all classes of ARV probably indicates an increase in genotypic assay use in ARV-naive individuals, however, the trends and correlations in this data set were similar when evaluated after removal of genotypically sensitive strains. Continued monitoring of ARV resistance prevalence, patterns, and utilization trends in clinical databases provides insight into the evolving relationship between clinical practice and ARV resistance.Keywords
This publication has 44 references indexed in Scilit:
- Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in SpainJournal of Clinical Microbiology, 2002
- Short Communication:Prevalence of G333D/E in Naive and Pretreated HIV-Infected PatientsAIDS Research and Human Retroviruses, 2002
- A Mutation in the 3′ Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor ResistanceJournal of Virology, 2002
- ATP-Dependent Removal of Nucleoside Reverse Transcriptase Inhibitors by Human Immunodeficiency Virus Type 1 Reverse TranscriptaseAntimicrobial Agents and Chemotherapy, 2002
- Genotypic and Phenotypic Analysis of a Novel 15-Base Insertion Occurring between Codons 69 and 70 of HIV Type 1 Reverse TranscriptaseAIDS Research and Human Retroviruses, 2002
- Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 IsolatesAntimicrobial Agents and Chemotherapy, 2002
- Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug ResistanceClinical Microbiology Reviews, 2002
- Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside InhibitorsAntimicrobial Agents and Chemotherapy, 2002
- Impact of HIV Type 1 Drug Resistance Mutations and Phenotypic Resistance Profile on Virologic Response to Salvage TherapyAIDS Research and Human Retroviruses, 2001
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995